<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20190717044244N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2019-08-19</date_registration>
      <primary_sponsor>Ahvaz University of Medical Sciences</primary_sponsor>
      <public_title>Fasting mimicking diet compared with low calorie diet among premenopausal obese women</public_title>
      <acronym></acronym>
      <scientific_title>The effects of fasting mimicking diet versus low calorie diet on anthropometric measurements, body composition, insulin sensitivity and regulatory hormones of food intake on premenopausal obese women</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2019-08-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>60</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/40881</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Other design features: As the study is a diet intervention trial, it is not possible to blind the personnel. However, study personnel involved in data collection and specimen analysis will be blinded to group assignments, Randomization description: Patients will randomly assigned to the 2 groups. Every patient will receive a code number. The the codes were written on concealed letters and will be chosen by a second person and assign randomly to one of the study groups.</study_design>
      <phase>N/A</phase>
      <hc_freetext>obesity.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: fasting mimicking diet will be administered during the first 5 days of a month (In total, 2 five-days cycles for 2 months). Fasting mimicking diet is a plant-based diet providing both micro- and macro- nutrients to decrease side-effects of fasting. It consists of a total of 1099 kcal (11% protein, 46% fat, 43% carbohydrate) in the first day, and a total of 717 kcal (9% protein, 44% fat, 47% carbohydrate) in the 4 following days. This will be provided by semi-prepared soups form Mahram and Elit companies. Also, a multi vitamin mineral from Supplex company and an omega3 supplement from Eurovital company will be provided during the 5 days of the cycle. Participants should continue their usual diet during the other 25 days of a month. Intervention 2: Control group: Calorie deficit of 500 kcal for 2 months. the diet will be a Mediterranean diet with 30-35% fat, 20% protein, and 45-50% carbohydrate (mostly from whole grains) emphasizing on vegetables, fruits, cereals, fish, poultry, nuts, olive oil, and limiting processed meats, red meats, and sweets.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is we can send data (after getting approval from the study PI) but it should be remained confidential. We are not allowed to publish data publically online.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mehdi Sadeghian</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Golestan</address>
        <city>Ahvaz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>61357-15794</zip>
        <telephone>+98 61 3373 8253</telephone>
        <email>mehdisad69@gmail.com</email>
        <affiliation>Ahvaz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mehdi Sadeghian</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Golestan</address>
        <city>Ahvaz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>61357-15794</zip>
        <telephone>+98 61 3373 8253</telephone>
        <email>mehdisad69@gmail.com</email>
        <affiliation>Ahvaz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>healthy women aged 18-50 years
BMI ranged from 30 to 35
not to use any tobacco
regular menstrual cycle
not to have symptoms of hyperandrogenism or PCOS
not to use contraceptive drugs
negative pregnancy test
not having metabolic disorder affecting gluconeogenesis
not having medical history of heart diseases
not having considerable food allergies
weight change less than 3 kg in the last 3 months
not having psychotic disorder affecting the patients' adherence</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>55 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>not to have adherence to the diet
unwilling to continue the trial</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>E66</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Overweight and obesity</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Lifestyle</i_code>
      <i_code>Lifestyle</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: fasting mimicking diet will be administered during the first 5 days of a month (In total, 2 five-days cycles for 2 months). Fasting mimicking diet is a plant-based diet providing both micro- and macro- nutrients to decrease side-effects of fasting. It consists of a total of 1099 kcal (11% protein, 46% fat, 43% carbohydrate) in the first day, and a total of 717 kcal (9% protein, 44% fat, 47% carbohydrate) in the 4 following days. This will be provided by semi-prepared soups form Mahram and Elit companies. Also, a multi vitamin mineral from Supplex company and an omega3 supplement from Eurovital company will be provided during the 5 days of the cycle. Participants should continue their usual diet during the other 25 days of a month.</i_keyword>
      <i_keyword>Control group: Calorie deficit of 500 kcal for 2 months. the diet will be a Mediterranean diet with 30-35% fat, 20% protein, and 45-50% carbohydrate (mostly from whole grains) emphasizing on vegetables, fruits, cereals, fish, poultry, nuts, olive oil, and limiting processed meats, red meats, and sweets.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Body weight. Timepoint: Body weight will be measured just before the inclusion in the trial and at the end of the intervention (after 2 months). Method of measurement: digital scale.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Body fat mass. Timepoint: Body fat mass will be measured just before the inclusion in the trial and at the end of the intervention (after 2 months). Method of measurement: Body composition analyzer.</sec_outcome>
      <sec_outcome>Fat free mass. Timepoint: Fat free mass will be measured just before the inclusion in the trial and at the end of the intervention (after 2 months). Method of measurement: Body composition analyzer.</sec_outcome>
      <sec_outcome>Serum glucose. Timepoint: Serum glucose will be measured just before the inclusion in the trial and at the end of the intervention (after 2 months). Method of measurement: enzymatic methods.</sec_outcome>
      <sec_outcome>Serum insulin. Timepoint: Serum glucose will be measured just before the inclusion in the trial and at the end of the intervention (after 2 months). Method of measurement: ELISA.</sec_outcome>
      <sec_outcome>Ghrelin. Timepoint: Serum ghrelin will be measured just before the inclusion in the trial and at the end of the intervention (after 2 months). Method of measurement: ELISA.</sec_outcome>
      <sec_outcome>Leptin. Timepoint: Serum leptin will be measured just before the inclusion in the trial and at the end of the intervention (after 2 months). Method of measurement: ELISA.</sec_outcome>
      <sec_outcome>Neuropeptide Y. Timepoint: Serum neuropeptide Y will be measured just before the inclusion in the trial and at the end of the intervention (after 2 months). Method of measurement: ELISA.</sec_outcome>
      <sec_outcome>Waist circumference. Timepoint: Waist circumference will be measured just before the inclusion in the trial and at the end of the intervention (after 2 months). Method of measurement: Meter.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Ahvaz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2019-03-12</approval_date>
        <contact_name>Ahvaz Jundishapur University of Medical Sciences</contact_name>
        <contact_address>golestan ahvaz Khouzestan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
